Eli Lilly › Eli Lilly (NYSE: LLY) has been a terrific stock to own over the past 15 years; it has consistently outperformed ...

If Lilly secures the full $100 million financial incentive, it would be the single largest award to date under the state’s ...

Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is ...

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...

Eli Lilly & Co. is tapping the US investment-grade debt market with a deal that’s expected to include a 40-year bond, a ...

Viking Therapeutics' dual-formulation obesity program could capture the most profitable patient segment starting in 2027. At 29 times forward earnings, Lilly stock assumes flawless execution with no ...

Eli Lilly looks attractively valued, with P/E ratios well below historical averages and robust momentum in Zepbound and ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

Viking Therapeutics stock tumbled after the drugmaker released study results of its experimental weight-loss pill.

Viking Therapeutics (VKTX) stock drops as its oral obesity drug VK2735 trails Novo's (NVO) oral Wegovy and Lilly's (LLY) ...

Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...

More than 80% of the potential $100 million in tax credits Eli Lilly could receive for its expansion in Kenosha County would ...